Any current/future new fundraising through debt or equity?

No explicit mention of new fundraising through debt or equity in the call. Management highlighted a focus on reducing corporate net debt substantially over the next 2 years. Debt reduced by INR 75 crores in the last 6 months, currently at 2.4x EBITDA, targeting below 2x within 12 to 18 months. CAPEX cycle largely complete; future CAPEX expected to be ₹50-75 crores in next two years, which is relatively moderate. For Zigly (Petcare business), management is exploring the possibility of raising external capital by setting it up as a separate subsidiary in FY27 to fund future growth, indicating po

Any current/future capex/capital investment/strategic investment?

The company has completed a strategic CAPEX cycle of ₹1,200 crore over the last 3 years. Further investment in new businesses (Plastech, Cosmo Consumer, Specialty Chemicals) is expected to be moderate, in the range of ₹50 to ₹75 crore over FY27 and FY28. FY27 CAPEX is expected to be less than ₹100 crore. Focus will be on "sweating" the strategic CAPEX already done, improving capacity utilization. No major new CAPEX planned; emphasis on growing high-margin, high-ROCE businesses. Plans to reduce corporate net debt substantially in the next 2 years, helped by lower future CAPEX. New consumer busi

Future growth expectations in sales/revenue/volumes?

Speciality sales expected to grow at a 10% CAGR year-on-year despite a higher base. Flexible Packaging (Film business) has a 15%-20% volume growth opportunity. Chemical business has potential to increase by close to INR 100 crores. Plastech business potential to grow by another 30%. Cosmo Consumer currently at 20% capacity utilization, indicating significant growth potential. New businesses (specialty chemicals, Plastech, Cosmo Consumer) scaling up, contributing to incremental ROCE. Demand for BOPET and BOPP expected to balance out in 12-18 months, with margins likely to improve. US business e

Future growth expectations in earnings/operating earnings/profits/EPS?

Cosmo First expects continued growth in Speciality sales at a 10% CAGR despite a growing base. Speciality Chemical business grew 20% in volume last year but slower value growth due to raw material price effects; EBITDA margins improved significantly. Plastech business expected to achieve high single-digit EBITDA in FY27 and mid-to-high teens EBITDA in FY28. Cosmo Consumer will remain loss-making in near term due to aggressive brand building; target to reach INR 100 crore revenue soon. Overall company ROCE impacted by recent CAPEX; expected to improve from 11% in FY26 to 14%-15% in FY27 and con

IN US

Sale is live|00:00:00left today

Cosmo First LtdQ1 FY26Industrial Products

Cosmo First Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹822P/E: 13.7Market Cap: ₹2.0K CrSector: Industrial Products

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Speciality sales expected to grow at a 10% CAGR year-on-year despite a higher base.
→Flexible Packaging (Film business) has a 15%-20% volume growth opportunity.
→Chemical business has potential to increase by close to INR 100 crores.
→Plastech business potential to grow by another 30%.
→Cosmo Consumer currently at 20% capacity utilization, indicating significant growth potential.
→New businesses (specialty chemicals, Plastech, Cosmo Consumer) scaling up, contributing to incremental ROCE.
→Demand for BOPET and BOPP expected to balance out in 12-18 months, with margins likely to improve.
→US business expected to grow at 15%-20% minimum.
→Cosmo Consumer targeting over 50% CAGR.
→Zigly and Plastech show strong double-digit top-line growth.
→Indian flexible packaging volumes growing at 8%-10% year-on-year.
→Overall, double-digit topline growth expected next year due to higher utilization and new business growth.

Margin guidance

Category 3

→Cosmo First expects continued growth in Speciality sales at a 10% CAGR despite a growing base.
→Speciality Chemical business grew 20% in volume last year but slower value growth due to raw material price effects; EBITDA margins improved significantly.
→Plastech business expected to achieve high single-digit EBITDA in FY27 and mid-to-high teens EBITDA in FY28.
→Cosmo Consumer will remain loss-making in near term due to aggressive brand building; target to reach INR 100 crore revenue soon.
→Overall company ROCE impacted by recent CAPEX; expected to improve from 11% in FY26 to 14%-15% in FY27 and continue rising with capacity ramp-up.
→Debt reduction is a priority; currently at 2.4x EBITDA, aimed to reduce below 2x within 12-18 months, improving financial resilience and profitability.
→Operating environment remains uncertain; margins in commodity segments like BOPET and BOPP remain volatile.
→One-off items affecting Q4 PAT will not recur, supporting better earnings in coming quarters.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→No explicit mention of new fundraising through debt or equity in the call.
→Management highlighted a focus on reducing corporate net debt substantially over the next 2 years.
→Debt reduced by INR 75 crores in the last 6 months, currently at 2.4x EBITDA, targeting below 2x within 12 to 18 months.
→CAPEX cycle largely complete; future CAPEX expected to be ₹50-75 crores in next two years, which is relatively moderate.
→For Zigly (Petcare business), management is exploring the possibility of raising external capital by setting it up as a separate subsidiary in FY27 to fund future growth, indicating potential equity raise there.
→Overall, the company aims to strengthen financial resilience and reduce reliance on debt rather than increasing it.

Order book

The transcript does not explicitly disclose details about the current or expected order book or pending orders for Cosmo First Limited. However, relevant insights related to growth and capacity utilization include: - Specialty sales are growing at a 10% CAGR year-on-year. - Current film business utilization is 80-85%, with potential to increase volumes by another 15-20%. - Chemical business has potential to grow by INR 100 crores. - Plastech capacity can grow by 30%, and Cosmo Consumer is at 20% capacity utilization indicating room to scale. - New business verticals such as Specialty Chemicals, Plastech, and Cosmo Consumer are scaling well. - Multiple new plants (7-8 lines) are expected to come live in the next 1-2 years. - US business expects 15-20% growth supported by removal of tariffs and new customer wins. Overall, strong capacity utilization and ongoing expansion suggest a healthy order inflow and growth outlook.

Capex plans

Yes

→The company has completed a strategic CAPEX cycle of ₹1,200 crore over the last 3 years.
→Further investment in new businesses (Plastech, Cosmo Consumer, Specialty Chemicals) is expected to be moderate, in the range of ₹50 to ₹75 crore over FY27 and FY28.
→FY27 CAPEX is expected to be less than ₹100 crore.
→Focus will be on "sweating" the strategic CAPEX already done, improving capacity utilization.
→No major new CAPEX planned; emphasis on growing high-margin, high-ROCE businesses.
→Plans to reduce corporate net debt substantially in the next 2 years, helped by lower future CAPEX.
→New consumer businesses like Zigly are being positioned for external capital to fund future growth, indicating potential strategic investments through subsidiaries.

How does Cosmo First Ltd rank vs peers in Industrial Products?

Pro feature

1Cosmo First Ltd

Rev 2Mar 3

See full Industrial Products sector rankings

Want more stocks like Cosmo First Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio